Welcome to our dedicated page for Electrocore SEC filings (Ticker: ECOR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
electroCore, Inc. filings document the regulatory record of a commercial-stage bioelectronic medicine and wellness company focused on non-invasive vagus nerve stimulation products. Current reports include financial results, guidance, preliminary estimates, and business updates tied to prescription sales, VA channel activity, direct-to-consumer Truvaga sales, and Quell product revenue.
The filings also cover capital-structure and governance matters, including common stock issuances, resale registration obligations, board composition, executive changes, and related material-event disclosures. These records describe electroCore’s operating performance, product commercialization, financing activity, and public-company governance framework.
electroCore, Inc. former officer and director Daniel S. Goldberger reported an open-market sale of 80,000 shares of common stock at a weighted average price of $6.80 per share. According to the filing, these shares were sold in multiple transactions at prices ranging from $6.00 to $8.52 per share between April 23, 2026 and May 26, 2026, subject to Rule 144. Following these transactions, he directly holds 211,471 shares of electroCore common stock.
electroCore, Inc. Chief Financial Officer and Interim President Joshua S. Lev reported an open-market sale of 6,667 shares of Common Stock on May 28, 2026 at a weighted average price of $9.00 per share.
After this transaction, he directly owned 84,889 shares, including 2,889 shares of Common Stock and 82,000 shares issuable under previously granted RSUs that vest over several dates through late 2029, subject to continued service and certain change-in-control conditions.
electroCore, Inc. filed a Form 144 notice reporting insider transactions in Common Stock. The filing lists Restricted Stock Units granted on 01/12/2024 (5,334 RSUs) and 01/15/2025 (1,333 RSUs) and records a sale of 3,000 shares on 05/22/2026 for $19,500.
The excerpt also lists Common Stock information with an adjacent figure 8,295,707 and the date 05/27/2026; the filing shows the transactions and grant dates but does not state additional proceeds treatment or broader offering mechanics.
ECOR filed a Form 144 notice reporting proposed sales of Common stock by holders who received shares as payment for services rendered and as compensation. The excerpt lists multiple grant dates and amounts, including several 3,333-share entries and a 72,034-share grant dated 05/16/2026.
electroCore director Thomas J. Errico increased his stake in the company through open-market buying. On May 21, 2026, he purchased 9,992 shares of electroCore common stock at $5.99 per share in an open-market transaction. This followed a small acquisition of 8 shares on May 20, 2026 classified under Rule 16a-6.
After these transactions, Errico directly owns 360,071 shares of common stock. A footnote explains that his broader holdings also include 259,106 shares owned directly, 1,296 shares held by a family trust, 11,000 shares in a trust for his benefit, 8,872 unvested shares underlying deferred stock units, and 69,797 shares that have vested from previously issued deferred stock units.
electroCore, Inc. executive Joshua S. Lev, the CFO and Interim President, sold 3,000 shares of Common Stock at $6.50 per share on May 22, 2026. According to the filing, this sale was made solely to cover tax withholding obligations triggered by the vesting and settlement of previously granted Restricted Stock Units.
After the transaction, Lev directly holds 91,556 shares of Common Stock. He also has 82,000 additional shares subject to RSUs scheduled to vest between December 31, 2026 and January 26, 2029, contingent on continued service and certain change-in-control protections.
ECOR filed a Form 144 reporting a proposed sale of 45,000 shares of Common Stock. The filing lists Charles Schwab & Co as the broker and an aggregate value of $291,600 with a filing date shown as 05/14/2026.
The filing also records a prior sale by Daniel Goldberger of 16,072 shares on 04/10/2026 for $96,753. The 45,000 shares are linked to an Equity Compensation entry dated 06/30/2021.
electroCore, Inc. reported strong top-line growth but ongoing losses and liquidity risk for the quarter ended March 31, 2026. Net sales rose 43% year over year to $9.6 million, driven mainly by U.S. prescription devices, especially sales to the Department of Veterans Affairs.
Gross margin improved to 87%, yet operating expenses increased to $13.7 million, leading to a net loss of $5.3 million and a stockholders’ deficit of $5.7 million. Cash, cash equivalents and marketable securities totaled $8.8 million, and management disclosed “substantial doubt” about the company’s ability to continue as a going concern without additional capital or cost reductions.
electroCore, Inc. reported strong first quarter 2026 growth, with net sales of $9.6 million, up about 43% from $6.7 million a year earlier, led by VA prescription gammaCore, Quell Fibromyalgia, and Truvaga wellness products. Gross margin expanded to 87%, lifting gross profit to $8.4 million.
The company still posted a GAAP net loss of $5.3 million, or $0.59 per share, reflecting higher operating expenses, including $1.9 million of one-time leadership transition costs and legal fees. Adjusted EBITDA net loss improved to $2.3 million, and management reaffirmed full-year 2026 revenue growth guidance of about 30% over 2025.
electroCore, Inc. Schedule 13G reports that Hilve Holdings Ltd (and its sole shareholder Mikhail Stiskin) beneficially own 517,522 shares of Common Stock, representing 6.4% of the outstanding shares. The percentage is calculated using 8,083,558 shares outstanding as of March 13, 2026.
The filing states Hilve Holdings Ltd has sole voting and dispositive power over the 517,522 shares. Signature blocks show the report was signed on 05/05/2026 by an authorized director and by Mr. Stiskin.